MARKET

ABBV

ABBV

Abbvie Inc
NYSE
178.49
+0.61
+0.34%
After Hours: 177.60 -0.89 -0.50% 19:44 03/18 EDT
OPEN
179.01
PREV CLOSE
177.88
HIGH
179.88
LOW
177.57
VOLUME
8.57M
TURNOVER
0
52 WEEK HIGH
182.89
52 WEEK LOW
127.03
MARKET CAP
315.30B
P/E (TTM)
65.66
1D
5D
1M
3M
1Y
5Y
IXJ: Healthcare Sector Dashboard For March
IShares Global Healthcare ETF is overvalued by about 13% relative to 11-year averages. Healthcare equipment has the worst value and quality scores. The healthcare sector is the most overvalued in the U.S. In March 2024. This monthly article series shows a dashboard with aggregate industry metrics in healthcare.
Seeking Alpha · 15h ago
SCHD: Reconstitution But Familiar Names Remain, Still Generating Additional 'Income'
Schwab U.S. Dividend Equity ETF™ recently underwent its annual reconstitution. The fund provides exposure to a value-oriented portfolio and has delivered an attractive yield of 3.77%. Many familiar names remain in the fund's top ten, including Coca-Cola and Pfizer.
Seeking Alpha · 15h ago
SCHD's Reconstitution Adds Too Many Stocks With Mediocre Quant Ratings
The Schwab U.S. Dividend Equity ETF has eliminated and replaced 23 stocks contributing 1/5 of its dividend. Four of the added stocks are flagged as very risky by Seeking Alpha's Quant rating system. Broadcom and Merck were eliminated from the SCHD's top 10 largest holding.
Seeking Alpha · 16h ago
Interesting ABBV Put And Call Options For March 2025
NASDAQ · 18h ago
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
NASDAQ · 20h ago
More Big Changes To My Dividend Growth Portfolio
Home Dividends Analysis Dividend Strategy More Big Changes To My Dividending Growth Portfolio. Nicholas Ward has been actively reshaping his portfolio by selling off low-conviction holdings. He has reduced his holdings from 90 to 70 in the past 6 months. Ward believes his changes will set up his portfolio for continued double-digit income growth.
Seeking Alpha · 22h ago
Weekly Report: what happened at ABBV last week (0311-0315)?
Weekly Report · 1d ago
Survey finds GLP-1 users more inclined to get aesthetic procedures
Seeking Alpha · 1d ago
More
About ABBV
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, ELAHERE, IMGN-151, Pivekimab Sunirine and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities and more. The Company offers a PINK1 activator which is designed to address mitochondrial dysfunction.

Webull offers AbbVie Inc stock information, including NYSE: ABBV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABBV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABBV stock methods without spending real money on the virtual paper trading platform.